We therefore performed subgroup analyses and specifically analyzed suPAR concentrations in patients with different tumor localization (Figure 2A) with lower or higher Ki-67 rates (Figure 2B), histological grade 1 to 3 tumors (Figure 2C), functional or non-functional disease (Figure 2D) as well as positive or negative somataostatin receptor (SSR) expression status (Figure 2E). The gene discussed is MKI67; the disease is neoplasm.